CVRx Reports Q3 2026 Revenue Decline Amid Reimbursement Headwinds
CVRx (CVRX) reported third-quarter 2026 financial results characterized by a decline in total revenue to $13.8 million, a 6.1% decrease year-over-year. The company faced significant challenges regarding reimbursement from its largest Medicare Advantage payer, where the 30-day prior authorization approval rate plummeted to 12% compared to 83.5% in the previous year. This headwind, combined with sales force productivity issues and physician turnover, contributed to a net loss of $14.2 million. Despite these operational hurdles, CVRx maintained a strong gross margin of 87% and expanded its U.S. footprint to 262 active implanting centers. However, the company lowered its full-year 2026 revenue guidance to a range of $56 million to $57 million. Management noted that while reimbursement delays have impacted short-term performance, they maintain an estimated 18-month cash runway based on current expense reductions.
Tickers: $CVRX
Topics: financial results market headwinds operating expenses revenue decline